NASDAQ · PRCT
Healthcare · Medical - Devices
$17.02
Down-$1.20 (-6.59%)
Updated Oct 2, 2026, 6:10 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRCT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
PRCT closed at $17.02 after 20 trading sessions, down 20.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $18.26 | $18.46 | $16.74 | $17.02 | 1.6M |
| Sep 30, 2026 | $18.09 | $18.50 | $17.685 | $18.22 | 1.59M |
| Sep 29, 2026 | $17.37 | $18.67 | $16.80 | $18.22 | 2.19M |
| Sep 28, 2026 | $17.23 | $17.46 | $16.80 | $17.25 | 1.75M |
| Sep 25, 2026 | $17.37 | $17.69 | $17.05 | $17.20 | 1.95M |
| Sep 24, 2026 | $18.22 | $18.396 | $17.2501 | $17.50 | 1.35M |
| Sep 23, 2026 | $18.34 | $18.62 | $17.945 | $18.09 | 914.7K |
| Sep 22, 2026 | $18.87 | $19.20 | $18.40 | $18.43 | 1.17M |
| Sep 21, 2026 | $19.31 | $19.38 | $18.405 | $18.51 | 1.11M |
| Sep 18, 2026 | $19.42 | $19.5107 | $18.99 | $19.30 | 1.49M |
| Sep 17, 2026 | $19.58 | $19.58 | $19.04 | $19.47 | 850.08K |
| Sep 16, 2026 | $19.20 | $19.96 | $18.9037 | $19.44 | 1.3M |
| Sep 15, 2026 | $20.82 | $20.91 | $19.23 | $19.30 | 2M |
| Sep 14, 2026 | $20.58 | $21.50 | $20.58 | $21.02 | 1.68M |
| Sep 11, 2026 | $20.23 | $20.67 | $19.55 | $20.38 | 1.57M |
| Sep 10, 2026 | $20.42 | $20.65 | $19.76 | $20.07 | 975.55K |
| Sep 9, 2026 | $21.22 | $21.44 | $20.60 | $20.74 | 1.07M |
| Sep 8, 2026 | $22.485 | $22.56 | $20.85 | $21.35 | 1.78M |
| Sep 4, 2026 | $21.19 | $22.835 | $20.89 | $22.76 | 1.28M |
| Sep 3, 2026 | $22.13 | $22.49 | $20.84 | $21.37 | 861.09K |
The latest Smart Investors Daily articles mentioning PRCT.
Company
Market Activity
Research & News
PRCT research
Company profile and research snapshot.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | William Blair | Market Perform | — |
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Aug 5, 2026 | TD Cowen | Buy | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Jul 6, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Mar 30, 2026
PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.
SeekingAlpha · Mar 6, 2026
PROCEPT BioRobotics Corporation (PRCT) TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, CEO...
Benzinga · Mar 6, 2026
Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $30.
SeekingAlpha · Mar 4, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRCT.
